Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data
Science Advances · 2024
DOI: 10.1126/sciadv.adk1894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Advances, 2024. Verfasst von Baron Rubahamya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Antibody drug conjugates (ADCs) have made impressive strides in the clinic in recent years with 11 Food and Drug Administration approvals, including 6 for the treatment of patients with solid tumors. Despite this success, the development of new agents remains challenging with a high failure rate in the clinic. Here, we show that current approved ADCs for the treatment of patients with solid tumors can all show substantial efficacy in some mouse models when administered at a similar weight-based [milligrams per kilogram (mg/kg)] dosing in mice that is tolerated in the clinic. Mechanistically, equivalent mg/kg dosing results in a similar drug concentration in the tumor and a similar tissue penetration into the tumor due to the unique delivery features of ADCs. Combined with computational approaches, which can account for the complex distribution within the tumor microenvironment, these scaling concepts may aid in the evaluation of new agents and help design therapeutics with maximum clinical efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Baron Rubahamya, Greg M Thurber
Förderung
- NIGMS NIH HHS
Zitieren
APA
Rubahamya, B., Dong, S., & Thurber, G. M. (2024). Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Science Advances. https://doi.org/10.1126/sciadv.adk1894
Vancouver
Rubahamya B, Dong S, Thurber GM. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Science Advances. 2024. doi:10.1126/sciadv.adk1894
BibTeX
@article{Rubahamya2024,
author = {Rubahamya, Baron and Dong, Shujun and Thurber, Greg M},
title = {Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adk1894}
}
EUVIMED